Scarica l'app Stockscreener
30.34
2.95%
0.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$29.47
Aprire:
$29.31
Volume 24 ore:
2.06M
Relative Volume:
1.69
Capitalizzazione di mercato:
$2.90B
Reddito:
$305.00K
Utile/perdita netta:
$-328.98M
Rapporto P/E:
-7.1134
EPS:
-4.2652
Flusso di cassa netto:
$-309.60M
1 W Prestazione:
+5.46%
1M Prestazione:
+26.31%
6M Prestazione:
+122.11%
1 anno Prestazione:
+54.64%
Intervallo 1D:
$29.00
$30.77
Intervallo di 1 settimana:
$28.33
$30.77
Portata 52W:
$9.90
$30.77
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta VRDN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
30.34 | 2.81B | 305.00K | -328.98M | -309.60M | -4.2652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Iniziato | TD Cowen | Buy |
| 2024-09-11 | Reiterato | Needham | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-05-09 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Iniziato | BTIG Research | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-17 | Iniziato | Wells Fargo | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2022-12-19 | Iniziato | Cowen | Outperform |
| 2022-12-19 | Iniziato | Needham | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-12-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-11-18 | Iniziato | SVB Leerink | Outperform |
| 2021-10-12 | Iniziato | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 39% Price Boost Is Out Of Tune With Revenues - simplywall.st
Viridian Therapeutics stock hits 52-week high at $30.15 By Investing.com - Investing.com Nigeria
Viridian Therapeutics stock hits 52-week high at $30.15 - Investing.com India
Discipline and Rules-Based Execution in VRDN Response - news.stocktradersdaily.com
Is Viridian Therapeutics Inc. stock attractive for hedge fundsDollar Strength & Stepwise Entry and Exit Trade Signals - newser.com
Is Viridian Therapeutics Inc. stock cheap at current valuation2025 Sector Review & Daily Chart Pattern Signal Reports - newser.com
How Viridian Therapeutics Inc. (1S1) stock compares with top peersJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
Is Viridian Therapeutics Inc. stock attractive for growth ETFsJuly 2025 WrapUp & Daily Volume Surge Trade Alerts - newser.com
Will Viridian Therapeutics Inc. stock benefit from sector rotationQuarterly Portfolio Summary & Weekly High Return Stock Opportunities - newser.com
Why Viridian Therapeutics Inc. (1S1) stock is favored by hedge fundsQuarterly Portfolio Review & High Return Trade Guides - newser.com
Will Viridian Therapeutics Inc. stock remain a Wall Street favoriteMarket Rally & High Yield Equity Trading Tips - newser.com
Will Viridian Therapeutics Inc. stock keep outperforming rivals2025 Trade Ideas & High Win Rate Trade Tips - newser.com
Viridian Therapeutics at Jefferies Conference: Strategic TED and FcRn Developments - Investing.com Canada
Regression analysis insights on Viridian Therapeutics Inc. performance2025 Investor Takeaways & Safe Capital Growth Stock Tips - newser.com
Can machine learning forecast Viridian Therapeutics Inc. recoveryWeekly Stock Summary & Safe Swing Trade Setup Alerts - newser.com
How Viridian Therapeutics Inc. stock performs in interest rate cycles2025 Price Targets & Breakout Confirmation Trade Signals - newser.com
How buybacks impact Viridian Therapeutics Inc. stock valueJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
4DMT Appoints Kristian Humer as Chief Financial Officer - GlobeNewswire Inc.
RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results - Finviz
Trend analysis for Viridian Therapeutics Inc. this weekWeekly Trade Review & Safe Entry Momentum Stock Tips - newser.com
Can swing trading help recover from Viridian Therapeutics Inc. lossesWeekly Stock Report & Precise Buy Zone Identification - newser.com
Why Viridian Therapeutics Inc. (1S1) stock is a must watch tickerForecast Cut & AI Based Buy and Sell Signals - newser.com
Viridian Therapeutics stock hits 52-week high at $29.27 By Investing.com - Investing.com Canada
Will Viridian Therapeutics Inc. (1S1) stock attract long term capital inflows2025 Retail Activity & Free Real-Time Market Sentiment Alerts - newser.com
Using Ichimoku Cloud for Viridian Therapeutics Inc. technicals2025 Market Overview & Technical Confirmation Alerts - newser.com
Viridian Therapeutics stock hits 52-week high at $29.27 - Investing.com India
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):